Kevin Kunzmann

The investigative solution improved patient metrics for itching, and could be considered for FDA submission later this year.

An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.

How the PIONEER-HF and PARADIGM-HF trials have focused on varied, but realistic heart failure patients.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

A new Puerto Rico-based trial shows that patients on add-on SGLT-2 inhibitors reported greater HbA1C reductions.

It's been 4 years since the drug class reached the market. Are patients adhering to the therapy, and what more potential does it have?

A new long-term data analysis reports that about 50% of patients adhere to the critcal therapy after just 1 year, and the rate continues to drop after that.

What researchers from the low-risk TAVR trial anticipate they will find in their decade-long assessment.

With cardiovascular drug classes inhibitors owning discussion, how will recent or upcoming guideline updates address their use alongside lifestyle management?

The 60-hour intravenous therapy becomes the first drug indicated for postpartum depression.

Progress in invasive measures for cardiovascular conditions has allowed clinicians the ability to venture into new ground.

What plans are held to progress the impressive findings of an envelope for cardiovascular device infection?

An extension of the study showed sacubitril/valsartan's benefit as an initial hospitalized heart failure therapy.

How alirocumab fared for patients with polyvascular disease in a subset of the major clinical trial.

Heart disease is the greatest cause of death in women, and Wood believes female patients would better from a multidisciplinary approach.

How an antibiotic envelope can address concerns of infection in cardiovascular devices.

What do some of the findings from one of the biggest presentations at ACC mean for the state of valve replacement care?

Why every care provider must be able to prepare for and commit to an "emergency protocol" in the face of adversity.

New recommendations for prevention focus on risk factors, new therapies, and press against the popular use of aspirin as a preventive therapy.

Now that SGLT-2 inhibitors have reached the market, how will clinicians compare their benefits in patients?

How is telehealth already influencing how some hospitals manage cardiovascular concerns?

How advancing stent therapy options have come to bridge the gap between improving and elongating a patient's life.

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A system which rewards hospitals based on their patient readmission rates may not be considering other factors of care.

The Janssen therapy was significantly more beneficial for atrial fibrillation patients than warfarin.

A new study reports an independent association between air pollution and arterial inflammation—and that the former could serve as a predictor to events like stroke and myocardial infarction.

No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.

Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?

The Acticor and Rivacor brands from BIOTRONIK have become the smallest, slimmest 3 Tesla MR-conditional CRM devices on the US market.

The National Cancer Institute director will assume temporary leadership after Scott Gottlieb, MD, departs next month.